Litigation Details for MOLINA HEALTHCARE, INC. v. CELGENE CORPORATION (D.N.J. 2022)
✉ Email this page to a colleague
MOLINA HEALTHCARE, INC. v. CELGENE CORPORATION (D.N.J. 2022)
| Docket | ⤷ Try a Trial | Date Filed | 2022-07-13 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 28:1337 Sherman-Clayton Act | Assigned To | Esther Salas |
| Jury Demand | Plaintiff | Referred To | Michael A. Hammer |
| Patents | 6,045,501; 6,315,720; 6,561,976; 6,561,977; 6,755,784; 6,869,399; 7,141,018; 7,189,740; 7,230,012; 7,465,800; 7,468,363; 7,855,217; 7,959,566; 7,968,569; 8,204,763; 8,288,415; 8,315,886; 8,404,717; 8,530,498; 8,626,531; 8,648,095; 8,741,929; 9,056,120; 9,101,621; 9,101,622 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in MOLINA HEALTHCARE, INC. v. CELGENE CORPORATION
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in MOLINA HEALTHCARE, INC. v. CELGENE CORPORATION
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for MOLINA HEALTHCARE, INC. v. CELGENE CORPORATION (D.N.J. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-07-13 | 1 | Complaint | preventing the Revlimid ’501 Patent 6,045,501 4-Apr-00 … Patent, ’886 Patent, ’717 Patent, ’498 Patent, ’531 Patent, ’095 Patent, ’120 Patent, ’621 Patent, …its ’517 Patent, ’720 Patent, ’977 Patent, ’784 Patent, ’740 Patent, ’800 Patent, ’217 Patent, ’569 Patent…its ’720 patent, ’977 Patent, ’784 Patent, ’886 Patent, ’531 Patent, ’800 Patent, ’217 Patent, ’363 Patent…’s ’800 Patent, ’569 Patent, ’357 Patent, ’219 Patent, ’598 Patent, ’498 Patent, ’095 Patent, ’621 Patent | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
